With regulatory filings expected later this year for antibiotic dalbavancin, Durata Therapeutics Inc. continues to shore up its cash position. A month after inking a $20 million debt facility agreement, the Chicago-based biotech priced a $50 million public offering, selling 7.15 million shares priced at $7 apiece, a slight discount to Thursday's closing price. Read More
Researchers from Stanford University developed a method to render entire brains see-through and accessible to molecular labeling – a technical advance that will allow scientists to study anatomical and molecular interconnections between different brain regions without first slicing the brains and then attempting to reconstruct three-dimensional maps from the two-dimensional images. Read More
TAIPEI, Taiwan – With H7N9, Taiwan is facing another pandemic influenza threat from China. It's déjà vu all over again. On Friday, 43 people in the eastern part of China were infected with a new strain of avian flu that until now had been considered unable to be passed on to humans. Read More
Privately held Armetheon Inc. was launched in October 2011 with a mission to create novel antibiotics for drug-resistant bacteria. However, that program quickly took a back seat when the founders discovered a new use for a compound, tecarfarin, advanced by another biotech where several of them had played leading roles. Read More
Among the thousands of interesting people who will be attending the 2013 BIO International Convention in Chicago, which kicks off one week from today, are young standouts who are already making their mark in biotech. Read More
• Elorac Inc., of Vernon Hills, Ill., said the FDA granted fast-track designation to the company's naloxone topical lotion for the relief of pruritus in patients with cutaneous T-cell lymphoma (CTCL). Read More
• Pacira Pharmaceuticals Inc., of Parsippany, N.J., reported Phase IV (EXCLAIM) results for Exparel (bupivacaine liposome injectable suspension) in postsurgical analgesia. Read More
• Bristol-Myers Squibb Co., of New York, will invest $250 million to expand its large-scale biologics manufacturing facility in Devens, Mass., introducing biologics development and clinical trial manufacturing capabilities and adding about 350 employees. Read More
• Iroko Pharmaceuticals LLC, of Philadelphia, will present positive Phase III data for its nonsteroidal anti-inflammatory drug pipeline at two medical meetings summarizing studies of submicron indomethacin and submicron diclofenac for osteoarthritis pain. Read More
